DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
The DOI matches its Crossref record; 105 of the 107 references it cites were found in a registry or an index.
Abstract
Our results suggest that between 29% and 46% of depressed patients fail to respond fully with antidepressant treatment of adequate dose and duration. In particular, although partial response appears to occur in 12% to 15% of the depressed patients studied, nonresponse is observed in 19% to 34% of this population. The prevalence of treatment-resistant depression derived from studies using ITT analysis is likely to be an overestimate of the actual occurrence of the phenomenon, as these rates also reflect the outcome of patients who were treated inadequately or were intolerant to the treatment. On the other hand, data derived from studies using completer analysis are likely to generate under-estimates of the prevalence of this phenomenon, as patients may have dropped out before completion of the study due to lack of efficacy. One could, therefore, guess that the actual rates of treatment resistance in the clinical population of depressed patients probably lie between these two types of estimates. From an epidemiologic point of view, because the prevalence of depression has been estimated to vary from 2.6% to 5.5% in men and from 6.0% to 11.8% in women, one must conclude that treatment-resistant depression is a very common clinical problem that is likely to affect more than one third of depressed patients. In summary, treatment-resistant depression patients can be defined as those who fail to respond to standard doses (i.e., significantly superior to placebo in double-blind studies) of antidepressants administered continuously for at least 6 weeks. Additional requirements of this operational definition are an accurate diagnosis of depressive disorder, patient compliance with the treatment, the use of valid outcome measures, and therapeutic range of antidepressant blood levels for the tricyclic antidepressants. Finally, symptomatic improvement that is equal or greater than 25% and less than 50% qualifies as partial response, and less than 25% symptomatic improvement is complete nonresponse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, all the monoamine-based antidepressant drugs, regardless of their pharmacological class, have fundamentally comparable modest efficacy, with response rates hovering around 50%, and exhibiting a characteristic delayed (typically over several weeks) response to treatment 16,161 .”
From Major depressive disorder (2016) · cites this paper as [161]
In the citing paper
“Following treatment with antidepressant drugs, only half of patients are noted to have a significant clinical response.6,7”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [7]
In the citing paper
“Although the burden and disability related to this condition, the STAR*D study clearly showed that about 50% of patients with major depressive disorder (MDD) will experience a response with the first treatment [3] but only 30% achieve a complete remission and the remaining percentage will need to undergo several additional treatment trials in order to improve response [4].”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [3]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Handbook of affective disorders
Paykel, E. S. (1982) · Medical Entomology and Zoology · Cited by 613
Treatments of Depression and the Functional Capacity to Work
Mintz, J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100005001 · Cited by 563
Mynors-Wallis, L. M., Gath, D. H., Lloyd-Thomas, A. R., & Tomlinson, D. (1995) · BMJ · doi:10.1136/bmj.310.6977.441 · Cited by 492
Handbook of Affective Disorders
Nasrallah, H. A. (1993) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199311000-00026 · Cited by 442
Antidepressant Specificity in Atypical Depression
Liebowitz, M. R. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800260037004 · Cited by 348
Research works printed but not linked: 2
- Fava M, Kaji J, Davidson K: Clinical strategies for treatment resistant unipolar depression. In Pollack M, Rosenbaum J (eds): Clinical Challenges in Psychiatric Medicine. New York, Guilford Publications, in press
- Ferguson, 1994, Dothiepin versus doxepin in major depression: Results of a multicenter, placebo-controlled trial, J Clin Psychiatry, 55, 258
Cited by
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationDeep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Self-citationPRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Self-citation
Metadata
- Authors
- Fava, M., & Davidson, K. G.
- Venue
- Psychiatric Clinics of North America
- Publisher
- Elsevier BV
- Published
- 1996-06
- Volume
- 19
- Issue
- 2
- Pages
- 179-200
- ISSN
- 0193-953X (ISSN-L)
- OpenAlex
- W1966424565
- Cited by
- 797
- References
- 107
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 33 · 2023: 40 · 2022: 37 · 2021: 31 · 2020: 23 · 2019: 32 · 2018: 29 · 2017: 24 · 2016: 34 · 2015: 39 · 2014: 35 · 2013: 31 · 2012: 40
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Psychiatric Clinics of North America (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- treatment-resistant depression, antidepressant response, treatment failure, medication adherence, plasma drug concentration, tricyclic antidepressants, major depressive disorder, psychiatric comorbidity, psychosocial stressors, remission, functional outcome, mood disorders
- MeSH terms
- Antidepressive Agents, Chronic Disease, Clinical Trials as Topic, Depressive Disorder, Double-Blind Method, Drug Resistance, Female, Humans, Male, Prospective Studies, Surveys and Questionnaires, Recurrence, Retrospective Studies, Risk Factors, Comorbidity, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION. https://app.cochat.ai/papers/10.1016/s0193-953x(05)70283-5
- The paper
- Fava, M., & Davidson, K. G. (1996). DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION. Psychiatric Clinics of North America. https://doi.org/10.1016/s0193-953x(05)70283-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.